Actinium Pharmaceuticals Inc (NYSEMKT: ATNM)
Actinium Pharmaceuticals (ATNM) is continuing upon its aggressive informational campaign to tout the potential benefits of Iomab-B, ATNM’s lead clinical compound. Iomab-B is currently being studied in a 150-patient, multicenter phase III pivotal trial, in patients with relapsed or refractory acute myeloid leukemia who are age 55 and above. The meetings are scheduled to take place on February 22-26, 2017 in Orlando , Florida.
Presenting At BMT Tandem Meetings
The BMT Tandem Meetings will provide ATNM with a targeted audience that host worldwide experts in blood and marrow transplant care, clinical investigation and laboratory research. The annual event is one of the largest gatherings of industry experts in North America, with over 3000 transplant physicians from over 500 transplant centers expected to attend.
Specifically, the BMT Tandem Meetings include an extensive scientific program that addresses state-of-the-art issues in bone marrow transplant and procedure. Attendees at this event include investigators, clinicians, laboratory technicians, clinical research professionals, and wide inclusion of other field specialists seeking to benefit from the meetings’ hematopoietic cell transplantation focused program.
For its part, ATNM will be represented by an encompassing team of professionals, comprised of clinical, medical, business development, and marketing personnel, with a coordinated plan to host a full agenda of activities related to ATNM’s advisory board meetings. ATNM will also command a booth presence for Iomab-B and its on-going SIERRA trial, with the booth providing advantages and aid in facilitating meetings with potential partners and collaborators.
Sandesh Seth, Executive Chairman of Actinium Pharmaceuticals believes that attendance at the BMT Tandem Meeting will prove beneficial, saying, “Our lead drug candidate, Iomab-B, is being developed to prepare patients for a bone marrow transplant with the hopes of enabling an increased number of elderly patients with relapsed or refractory leukemia to obtain a transplant compared to current salvage chemotherapy conditioning. Given our focus on transplant, the BMT Tandem meetings are a major event for us, which give us great insights into this exciting field while motivating us to all we can to improve outcomes for patients in need.”
ATNM And Iomab-B
Recently featured on CNA Finance, Iomab-B is Actinium’s lead product candidate, which is currently being studied in a 150-patient, multicenter pivotal Phase III clinical trial in patients with relapsed or refractory acute myeloid leukemia who are age 55 and above. Upon approval, Iomab-B is intended to prepare and condition patients for a bone marrow transplant, also referred to as a hematopoietic stem cell transplant, which is often considered the only potential cure for patients with certain blood-borne cancers and blood disorders.
ATNM has additional pipeline strength. The company’s second product candidate, Actimab-A, is currently in a multicenter open-label, 53-patient Phase 2 trial for patients newly diagnosed with AML age 60 and over. Actimab-A is being developed to induce remissions in elderly patients with AML who lack effective treatment options and often cannot tolerate the toxicities of standard frontline therapies. In addition, Actinium is developing Actimab-M, which is being studied in patients with relapsed or refractory multiple myeloma in a Phase 1 clinical trial. Actinium is also utilizing its alpha-particle immunotherapy (APIT) technology platform to generate new drug candidates based on antibodies linked to the element Actinium-225 that are directed at various cancers that are blood-borne or form solid tumors.
Stay focused to CNA Finance for additional breaking news coverage and clinical developments from ATNM.
Never Miss The News Again
Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!